Search
Choline magnesium trisalicylate
go.drugbank.com/drugs/DB01401ApprovedTrisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28% [A19653, A19654].
Tedizolid phosphate
go.drugbank.com/drugs/DB09042Approved[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Recombinant stabilized RSV B prefusion F antigen
go.drugbank.com/drugs/DB18714ApprovedInvestigational[L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]
Ozenoxacin
go.drugbank.com/drugs/DB12924Approveds Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age
Moexipril
go.drugbank.com/drugs/DB00691ApprovedInvestigationalIt works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Mixtures: FEMPRESS PLUS 15MG/25MGMetacycline
go.drugbank.com/drugs/DB00931ApprovedA broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.
Chikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigationalcaused by chikungunya virus. … [A262051] It is spread primarily by the bite of infected mosquitos of the _Aedes_ genus.
Siponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigationalSymptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. … It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020.
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]